Ukrainian Drones and the #MadeByHousewives Movement: Kyiv Fires Back at Rheinmetall CEO 
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 
Europe's Aviation Sector on Track to Meet 2025 Green Fuel Mandate 
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover 
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push 
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown 
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal 
Apple Turns 50: From Garage Startup to AI Crossroads 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
First Western Ship Transits Strait of Hormuz Since Iran War Began 
Samsung Electronics Eyes Record Q1 Profit Amid AI-Driven Chip Boom 
Luxury Car Sales in the Middle East Take a Hit Amid Iran War 
CAMBRIDGE, Mass., Sept. 26, 2016 -- Vericel Corporation (Nasdaq:VCEL), a leading developer of autologous cellular therapies for the treatment of severe diseases and conditions, today announced that Nick Colangelo, president and CEO, will present at the annual Cell & Gene Meeting on the Mesa at the Estancia La Jolla Hotel & Spa in La Jolla, CA on Wednesday, October 5, 2016 at 5:45pm Pacific time.
Organized by ARM and the Sanford Consortium for Regenerative Medicine, the Cell & Gene Meeting on the Mesa is a three-day conference organized specifically for the cell and gene therapy and regenerative medicine sector.
The presentation will be webcast live at: http://www.meetingonthemesa.com/webcast/ and will also be published on ARM’s website shortly after the event.
About Vericel Corporation
Vericel develops, manufactures, and markets autologous expanded cell therapies for the treatment of patients with serious diseases and conditions. The company markets two cell therapy products in the United States. Carticel® (autologous cultured chondrocytes) is an autologous chondrocyte implant for the treatment of cartilage defects in the knee in patients who have had an inadequate response to a prior arthroscopic or other surgical repair procedure. Epicel® (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. Vericel is also developing two additional cell products. MACI® is a third generation autologous chondrocyte implant intended to treat cartilage defects in the knee. Ixmyelocel‑T is an autologous multicellular therapy intended to treat advanced heart failure due to ischemic dilated cardiomyopathy (DCM). For more information, please visit the company's website at www.vcel.com.
Epicel®, Carticel® and MACI® are registered trademarks of Vericel Corporation. ©2016 Vericel Corporation. All rights reserved.
CONTACT: Chad Rubin The Trout Group [email protected] (646) 378-2947 or Lee Stern The Trout Group [email protected] (646) 378-2922
